← Back

Wire · opportunities

Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Merck and Kelun-Biotech's antibody drug conjugate sacituzumab tirumotecan (sac-TMT) significantly improved overall survival in a Phase 3 trial for advanced gastroesophageal cancer, marking a key regulatory milestone and expanding its potential global market. Despite missing secondary endpoints, sac-TMT advances Merck's wider TroFuse program targeting multiple cancers and aligns with their plans for regulatory submissions.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You need to pivot towards therapies improving overall survival for tough cancers as sac-TMT's FDA priority review shows regulators now favour OS data over secondary endpoints. Your development plans must reflect this if you want to clear regulatory hurdles and expand market access.

◆ Coverage

2 sources · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechoncologyantibody-drug-conjugateclinical-trialregulatory-approvalcancer-treatment